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Abstract
Bone marrow–derived mesenchymal stem cells (MSCs) have been shown to localize to gliomas and deliver thera-
peutic agents. However, the clinical translation of MSCs remains poorly defined because previous studies relied on
glioma models with uncertain relevance to human disease, typically xenograft models in immunocompromised
mice. To address this shortcoming, we used the RCAS/Ntv-a system, in which endogenous gliomas that recapitulate
the tumor and stromal features of human gliomas develop in immunocompetent mice. MSCs were harvested from
bonemarrow of Ntv-amice and injected into the carotid artery of Ntv-amice previously inoculated with RCAS–PDGF-B
and RCAS-IGFBP2 to inducemalignant gliomas (n=9). MSCswere labeledwith luciferase for in vivo bioluminescence
imaging (BLI). After intra-arterial injection, BLI revealed MSCs in the right frontal lobe in seven of nine mice. At nec-
ropsy, gliomas were detected within the right frontal lobe in all these mice, correlating with the location of the MSCs.
In the twomicewithoutMSCs based on BLI, no tumor was found, indicating thatMSC localizationwas tumor specific.
In another cohort of mice (n = 9), MSCs were labeled with SP-DiI, a fluorescent vital dye. After intra-arterial injection,
fluorescence microscopy revealed SP-DiI–labeled MSCs throughout tumors 1 to 7 days after injection but not in
nontumoral areas of the brain. MSCs injected intravenously did not localize to tumors (n = 12). We conclude that
syngeneicMSCs are capable of homing to endogenous gliomas in immunocompetent mice. These findings support
the use of MSCs as tumor-specific delivery vehicles for treating gliomas.
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Introduction
Despite multimodal therapy, patients with high-grade gliomas have a
poor prognosis, with a median survival of 14 months for grade 4 and
36 months for grade 3 gliomas according to the World Health Orga-
nization [1,2]. This poor outcome is due at least in part to an inability
to deliver therapeutic agents to the infiltrative tumor cells. Delivery of
most conventional therapies is restricted by the blood-brain-tumor
barrier, and the efficacy of newer biologic therapies, such as gene
and viral therapies, has been limited by the inability to deliver the
therapeutic genes to most of the tumor [3]. Consequently, significant
efforts have been undertaken to develop new methods for delivering
therapeutic agents to infiltrative gliomas [4].
Recent evidence has suggested that stem cells may be effective de-
livery vehicles for a variety of solid tumors arising throughout the
body. Initial studies of brain tumors indicated that neural stem cells
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have the capacity to migrate toward and deliver therapeutic agents to
human gliomas [5,6]. More recently, mesenchymal stem cells
(MSCs), acquired either from bone marrow or from adipose tissue,
have been explored as potential delivery vehicles in the treatment of
human gliomas [7]. MSCs are defined by their ability to grow as ad-
herent cells in culture, to express an array of positive and negative
surface markers, and to differentiate into adipocytes, chondrocytes,
and osteocytes under appropriate conditions [8,9]. Compared with
all other stem cells [10–12], MSCs have the clinical advantages that
they can be easily acquired from patients, are readily expanded ex vivo,
can be autotransfused without fear of immune rejection, and are free
of ethical concerns [13–15].
We [16] and others [17,18] have demonstrated the feasibility of
using human MSCs (hMSCs) as delivery vehicles for glioma therapy.
Specifically, hMSCs have been shown to be able to localize to malig-
nant gliomas after systemic delivery and to track infiltrating tumor cells
after local delivery [16]. The tropism of hMSCs for glioma seems to be
mediated at least in part by specific tumor-derived growth factors, par-
ticularly platelet-derived growth factor-BB [16,19]. Importantly, the
homing capacity of hMSCs can be translated into therapeutic benefit
because hMSCs can be engineered to deliver biologic antiglioma agents
to gliomas, including interferon β [16], S-TRAIL [18,20], and oncolytic
viruses [21], with demonstrable survival advantages [16,22].
Despite these promising results, the clinical translation of MSC-
based therapeutic approaches remains incompletely defined because
nearly all published studies analyzing the application of MSCs in glio-
mas have relied on tumor models that fail to recapitulate the genotypic
and/or phenotypic characteristics of human tumor cells and the micro-
environment in which they arise. The shortcomings of xenograft mod-
els of brain tumors for preclinical testing have been well described
[23,24]. To date, most studies analyzing the tropism of MSCs for
human gliomas have relied on commercially available human glioma
cell lines (e.g., U87, U251) that poorly mimic the invasive growth of
gliomas in patients. In addition, because these cell lines are grown as
xenografts in nude mice, the interaction of the tumor with the micro-
environment or stroma is, by necessity, artificial, raising concerns about
the true attraction of exogenously delivered MSCs for human gliomas.
Although a few studies have used newer human glioma stem cells
(GSCs) [18,25], which are derived directly from patient tumors and
grow as highly infiltrative tumors, GSCs must also be grown as xeno-
grafts in immunodeficient mice, which obviates the impact of the tu-
mor microenvironment and the immune system on MSC engraftment.
Syngeneic rodent models using commercially available murine gliomas
implanted in the brain have allowed for some assessment of immune
factors influencing MSC migration, but these models poorly recapitu-
late the genetics of human tumors, and thus their relevance to the hu-
man disease is questionable. These concerns call into question the
utility of these model systems for evaluating novel therapeutic strategies
[26,27]. Lastly, in all previous studies, MSCs have been injected within
only a few days of tumor implantation, making it difficult to differen-
tiate the ability of MSCs to localize to areas of injury resulting from the
process of cell implantation compared with localization to tumors in
their natural setting [28].
Since its initial description by Holland et al. [29], the RCAS/Ntv-a
system has been extensively used to model brain tumors (reviewed in
Becher and Holland [30]). This system uses a modified avian leukosis
virus (the replication-competent\, avian leukosis virus, splice acceptor
[RCAS] vector) to deliver genes of interest to brain cells in transgenic
mice that express the receptor (TVA) for the virus. TVA expression is
driven by the Nestin promoter, making glioneuronal precursor cells
specifically susceptible to infection and subsequent expression of an
inserted gene. This method of somatic cell gene transfer has been used
to model a variety of brain tumors [29,31–33]. In particular, somatic
transfer of RCAS–PDGF-B and RCAS-IGFBP2 results in murine
gliomas with all the histologic features of grade 4 gliomas identical
to human gliomas [34]. Activation of the PDGF-B and insulin-like
growth factor–binding protein 2 (IGFBP2) signaling pathways is rel-
evant in glioma because up to 30% of human gliomas demonstrate
evidence of aberrant PDGF expression [35,36], and most high-grade
human gliomas overexpress IGFBP2. Importantly, tumor cells in this
model have stem-like features and have been shown to reside within
the perivascular niche, indicating that the model faithfully recapitu-
lates the microenvironment and cellular interactions of human glio-
mas [37,38]. Recent work by our group has shown the benefit of
preclinical testing of agents with this model [39]. The RCAS/Ntv-a
system is ideal for studying the capacity of MSCs to home to gliomas
not only because the gliomas in this model recapitulate the phenotype
and genotype of human gliomas but also because the gliomas arise
endogenously within the native stroma of the brain in immunocom-
petent mice and permit natural interactions of MSCs with the sur-
rounding microenvironment [40,41].
Given the advantages of the RCAS/Ntv-a system, we sought to de-
termine the extent to which MSCs isolated from Ntv-a mice are ca-
pable of localizing to endogenous high-grade gliomas induced in the
brains of Ntv-a mice by somatic transfer of PDGF-B and IGFBP2.
Our results demonstrate that MSCs obtained from Ntv-a mice can
engraft endogenous brain tumors after systemic delivery, supporting
the evolving concept that MSCs have an intrinsic capacity to home
to gliomas.
Materials and Methods
Harvesting and Characterization of MSCs from Ntv-a Mice
MSCs were harvested using the technique described by Peister et al.
[42]. Briefly, the cells from the long bones of Ntv-a mice were isolated
and centrifuged at 1500 rpm. The pellet was then resuspended in α-
minimal essential medium (α-MEM) and 20% MSC supplement me-
dium (StemCell Technologies, Vancouver, British Columbia, Canada).
Cells were then plated in a T75 flask in α-MEM with 20%MSC sup-
plement medium and incubated at 37°C and 5% CO2. After 24 hours,
nonadherent cells were discarded; adherent cells were washed with PBS,
and fresh complete isolation medium was added every 3 to 4 days for
4 weeks. Cells were collected after trypsinization and replated in 30 ml
of complete isolation medium in 175-cm3 flasks. After 1 to 2 weeks,
passage 3 cells were either frozen or further expanded by plating at
50 cells/cm2 and incubating in the complete expansion medium. By
passage 4, cells were analyzed using FACS for the mesenchymal mark-
ers Sca-1 and CD9, the hematopoietic markers CD45 and CD11b, the
lymphocytic marker CD73, the endothelial markers CD31 and CD105,
and the GSC marker CD133. Cells were plated in α-MEM with 10%
fetal bovine serum (FBS) and supplemented with L-glutamine. Further
verification of a mesenchymal lineage was performed by plating the cells
in adipogenic, chondrogenic, and osteogenic media.
Differentiation Methods
Adipogenesis. Cells were seeded at 105 cells/μl in a six-well plate. At
100% confluence, cell differentiation was induced with supplemented
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adipogenesis induction medium (Lonza, Walkersville, MD) for 3 days,
followed by 3 days of culture in supplemented adipogenesis mainte-
nance medium (Lonza). After four cycles of induction/maintenance,
cells were rinsed with PBS, fixed with 10% buffered formalin, and
stained with Oil Red O.
Osteogenesis. Cells were seeded at 5 × 104 cells/μl in a six-well
plate. After 24 hours, cell differentiation was induced with the osteo-
genesis induction medium (Lonza). Cells were fed every 3 to 4 days
by completely replacing the medium with a fresh osteogenesis induc-
tion medium. After 3 to 4 weeks, cells were rinsed in PBS, fixed with
70% ethanol, and stained with Alizarin Red.
Chondrogenesis. Cell pellets were prepared by spinning down 3 ×
105 cells in 15-ml polypropylene tubes and growing the cells in the
complete chondrogenic medium (Lonza). Cell pellets were fed every
2 to 3 days by completely replacing the medium with a freshly pre-
pared complete chondrogenic medium. After 3 to 4 weeks, pellets
were fixed in buffered 10% formalin and embedded in paraffin. Then,
5-μm sections were slide-mounted and stained for glycosaminoglycans
with Safranin O.
Generation of Gliomas in Ntv-a Mice
Vector constructs. RCAS–PDGF-B was constructed with a hemag-
glutinin epitope tag as described previously [43]. Details of the cre-
ation of RCAS-IGFBP2 are described elsewhere [34]. Briefly, the
RCAS-IGFBP2 vector was constructed by subcloning the 1.4-kb com-
plementary DNA fragment of IGFBP2 into a Yap vector, which was
then transferred into the RCAS-X vector using NotI and ClaI restric-
tion enzymes. RCAS-GFP was provided by Dr Yi Li (Baylor College
of Medicine).
Transfection of DF-1 cells. DF-1–immortalized chicken fibro-
blasts were grown in Dulbecco modified Eagle medium with 10%
FBS (GIBCO, Carlsbad, CA) in a 5% CO2 humidified incubator
at 37°C. To produce live virus, plasmid versions of RCAS vectors were
transfected into DF-1 cells using FuGene6 (Roche, Nutley, NJ) and
allowed to replicate in culture.
In vivo somatic cell transfer in transgenic mice. Creation of the
transgenic Ntv-a mouse has been previously described [29]; the mice
are mixtures of the following strains: C57BL/6, BALB/C, FVB/N,
and CD1. To transfer genes through the RCAS vectors, DF-1 pro-
ducer cells transfected with a particular RCAS vector (105 cells in 1-
2 μl of PBS) were injected into the right frontal lobe of Ntv-a mice from
an entry point just anterior to the coronal suture of the skull using a
10-μl gas-tight Hamilton syringe. Equal numbers of DF-1 producer
cells for each vector (RCAS–PDGF-B or RCAS-IGFBP2) were coin-
jected to induce gliomas. Control mice were injected with RCAS-
GFP. To determine whether MSCs were themselves tumorigenic, we
coinjected RCAS–PDGF-B with bone marrow–derived MSCs from
Ntv-a mice. Escalating concentrations of MSCs (1 × 103, 1 × 104,
and 1 × 105) in 1 μl of α-MEM plus 10% FBS were coinjected with
RCAS–PDGF-B–infected producer cells (1 × 105 cells in 1 μl of PBS)
into cohorts of 30 mice each. A control group of 30 mice was injected
with RCAS–PDGF-B alone. We injected mice within 48 to 72 hours
after birth because the population of Nestin+ cells producing TVA re-
ceptors diminishes progressively with time. To identify the presence or
absence of tumor, we killed the mice by CO2 inhalation. Their brains
were removed, fixed in formalin, embedded in paraffin, stained with
hematoxylin and eosin (H&E), and analyzed for tumor formation
using light microscopy.
Systemic Delivery of MSCs to Ntv-a Mice
Between 6 and 10 weeks after RCAS vector injection, MSCs were
delivered into Ntv-a mice systemically either intra-arterially or intra-
venously. Intra-arterial delivery was performed by injecting MSCs
into the right common carotid artery using a technique described pre-
viously [16]. Mice were appropriately anesthetized (in accordance with
Institutional Animal Care andUse Committee guidelines) with ketamine/
xylazine, and the common carotid artery was visualized microscopically.
MSCs were trypsinized and suspended in α-MEM plus 10% FBS. The
cells were counted, and 106 MSCs suspended in 100 μl of medium
were injected into the carotid artery using a 30-gauge needle attached
to a tuberculin syringe. Mice were monitored until awake. For intrave-
nous delivery, MSCs were prepared as above, and 106 cells were injected
into the tail vein of mice.
In Vivo Visualization of MSC Engraftment
To visualize and track MSCs in live mice, Ntv-a MSCs were trans-
duced with an adenoviral vector containing the complementary DNA
of the firefly luciferase gene (Ad-Luc; 1000 virus particles per cell) be-
fore injection. Bioluminescence imaging (BLI) was used to detect the
MSCs. On the day of imaging, animals were treated with luciferin
(150 mg/kg, intraperitoneally) and imaged with the IVIS Imaging
System, 200 Series (Xenogen, Alameda, CA). Luciferase in cells con-
verts luciferin to oxyluciferin, generating a light signal that is detected
by a CCD camera. Bioluminescence color images were overlaid on
grayscale photographic images of the mice to allow for localization
of the light source within the animal using the Living Image version
2.11 software overlay (Xenogen) and IGOR image analysis software
(version 4.02A; WaveMetrics, Portland, OR). Mice were imaged 1, 4,
7, and 10 days after Ad-Luc MSC injection.
Histologic Confirmation of MSC Migration to Tumor
Histologic verification of MSC delivery to tumor-bearing brains
was performed by labeling MSCs with a fluorescent dye and analyzing
brains after MSC injection with fluorescence microscopy. SP-DiI
(Molecular Probes, Eugene, OR), a vital fluorescent dye that incorpo-
rates into the cell membrane, was dissolved in dimethylformamide at
21.5 mg/ml. The resulting solution was added to the culture medium
at 10 μg/ml. MSCs were incubated with 25 ml of medium with SP-DiI
in 175-cm3 flasks for 48 hours. A cohort of Ntv-a mice underwent
somatic cell transfer with RCAS–PDGF-B and RCAS-IGFBP2 to gen-
erate gliomas and were injected with SP-DiI–labeled MSCs (106 cells)
through the carotid artery at least 6 weeks after RCAS vector injection
and presumed tumor formation. Animals were killed 1, 4, 7, and 10 days
after MSC injection (n = 3 mice per group). Their brains were removed
and sectioned in the coronal plane. Half of the brain was fixed, dehy-
drated, and frozen with cryoembedding medium at −80°C. The other
half was fixed in formalin and stained with H&E. The sections stained
with H&E were analyzed to determine the presence of tumor. Frozen
sections were analyzed by fluorescence microscopy, and five 5-μm sec-
tions were obtained every 150 μm. In each of the five sections, the col-
onies of SP-DiI–labeled MSCs present throughout the tumor mass at
100× magnification were counted. Because it was difficult to distin-
guish single cells versus groups of cells, high-signal areas were counted
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as one colony. The median colony count for the five sections was calcu-
lated for each mouse at days 1, 4, 7, and 10 after intra-arterial injection.
To determine whether MSCs were present in other organs, we per-
formed intracarotid injections on mice and killed them at days 1, 4, 7,
and 10 after injection (n = 3 mice at each time point). The lungs, livers,
and spleens were removed and analyzed by fluorescence microscopy.
Statistical Methods
The median colony count of SP-DiI–labeled MSCs detected in the
tumor sections at different time points was compared using the Kruskal-
Wallis test. P < .05 was considered significant. The Kaplan-Meier
method was used to estimate the time to symptomatic tumor develop-
ment in mice. The log-rank test was used to compare the distributions,
and P < .05 was considered significant.
Results
Isolation and Characterization of Ntv-a MSCs
MSCs were harvested from the long bones of Ntv-a mice. In the
initial passages, the cells grew slowly, but by passage 7, the doubling
time was 24 to 36 hours and the cells had a spindle shape consistent
with the morphology described for human and other murine MSCs
(Figure 1A) [44,45]. Successful selection of MSCs was verified by their
differentiation into adipocytes or mineralizing osteocytes or chondro-
cytes when placed in differentiation medium (Figure 1, B-D). FACS
was performed on MSCs at passages 4, 6, 10, and 15 (Figure 2). By
passage 6, Sca-1 and CD9 were detected on 98.0% and 99.0% of cells,
respectively, and this high expression persisted so that by passage 15,
Sca-1 and CD9 were detected on more than 99.6% and 99.5% of cells,
respectively. CD105 was detected on 75.0% of cells at passage 6 but
only 10.0% of cells at passage 10. At passage 6, the hematopoietic
markers CD45 and CD11b were detected on 2.9% and 0.9% of the
cells, respectively, but by passage 10, these markers were not detected
on the cells. The endothelial marker CD31 and the GSC marker
CD133 were not detected at any passages. Thus, based on their mor-
phology, pattern of surface marker expression, and differentiation
capacity, the cells isolated from the bone marrow of the Ntv-a mice
were consistent with MSCs.
BLI Evaluation of MSCs after Intra-arterial Delivery
Animals were analyzed by BLI 1, 4, 7 and 10 days after MSC injec-
tion. BLI signal was detected over the right frontal lobe of seven mice at
each time point, whereas no signal was seen in two mice (Figure 3, A
and B). In the seven mice in which BLI signal was detected after
MSC injection, the median BLI signal intensity at day 1 was 6.3 ×
105 photons/sec per squared centimeter (range, 2.9 × 104 to 2.6 ×
106 photons/sec per squared centimeter). To verify that the signal arose
directly from the brain, brains were removed at day 4 or day 7 after
MSC injection and were reimaged. In all seven animals with positive
BLI signal after live imaging, the BLI signal was verified as originating
from the brain (Figure 3, A and B, right image). The median BLI in-
tensity at day 4 was 5.6 × 105 photons/sec per squared centimeter
(range, 2.9 × 105 to 1.5 × 107 photons/sec per squared centimeter)
and that at day 7 was 2.5 × 105 photons/sec per squared centimeter
(range, 2.5 × 104 to 9.8 × 105 photons/sec per squared centimeter).
In the mice imaged at day 10 after injection, we did not observe
any BLI signal. Two of the three mice in this group demonstrated
tumor formation.
Figure 1. Differentiation of Ntv-a–derived MSCs to mesenchymal tissue subtypes. (A) MSCs in stem cell medium after six passages.
(B) Bone formation fromMSCs after differentiation to osteoblastic cells after culture in an osteogenic medium. (C) Lipid droplet formation
fromMSCs after differentiation to adipocytes after culture in an adipogenic medium. (D) Cartilage formation fromMSCs after differentiation
to chondrocytes after culture in a chondroblastic medium.
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To determine which of the nine mice harbored tumors, the brains
were removed and stained with H&E. Because somatic cell transfer of
genes through RCAS vectors does not result in tumors in all mice, we
were able to use non–tumor-bearing mice as a control for MSC de-
livery. All seven animals with positive BLI signal (i.e., MSCs were de-
tected) demonstrated tumor formation within the right frontal lobe,
whereas in the brains of the two animals in which no signal was de-
tected (i.e., MSCs not present), tumors were not identified (Figure 3,
C and D). These results demonstrate that Ntv-a MSCs specifically
localized to gliomas generated endogenously in Ntv-a transgenic mice.
They also provide evidence that the MSCs that reside within the
tumor are viable because generation of a signal requires that the cells
express functional luciferase.
As a further control to show that Ntv-a MSCs localize specifically
to tumors, we injected a cohort of mice (n = 4) with RCAS-GFP and
performed intra-arterial injections of Ad-Luc–transfected MSCs
6 weeks later. We did not visualize any BLI signal in the brains of
these mice, and histological evaluation showed no evidence of tumor.
We also evaluated the ability of intra-arterially injected MSCs to
migrate to extracranial organs. A cohort of mice (n = 9) was injected
with Ad-Luc–transfected MSCs. At days 1, 4, 7, and 10 after injec-
tion, mice (n = 3 at each time point) were analyzed for BLI signal. The
mice were also killed, and the internal organs (including lungs, liver,
spleen, and abdominal viscera) were again analyzed for BLI signal. At
none of these time points did we observe BLI consistent with success-
ful migration of Ntv-a MSCs to these extracranial organs.
Histologic Evaluation of Ntv-a MSCs in Endogenous Gliomas
Another cohort of Ntv-a mice (n = 9) underwent somatic cell
transfer with RCAS–PDGF-B and RCAS-IGFBP2 and after 6 weeks
received intracarotid injection of Ntv-a MSCs stained with SP-DiI.
High-grade gliomas developed in all nine of the mice in this cohort.
SP-DiI–labeled MSCs were detected throughout the tumors but not
in nontumoral areas (Figure 4). At day 1, we identified a median of
7 colonies (range, 3-18 colonies) in the five frozen sections obtained
from each of the three mice killed at day 1. The median number of
MSC colonies was 9 (range, 3 to 43) at day 4 and also 9 (range, 0-21)
at day 7. No colonies were identified in any of the tumor-bearing
brains obtained from mice 10 days after injection. When the individ-
ual time points were compared, the difference between days 1 and 4
was significant (P = .02), but the difference between days 4 and 7 was
not significant (P = .1). The difference among the colony counts at all
time points was not significant (P = .07). The extent of tumor engraft-
ment by SP-DiI–labeled MSCs seemed to be associated with BLI sig-
nal intensity, with both peaking at around day 4 and disappearing by
day 10 (Figure 5).
We also determined whether SP-DiI–labeled MSCs migrated to
extracranial organs by injecting mice and visualizing the lungs, livers,
and spleens harvested from injected mice at days 1, 4, 7, and 10 (n = 3
at each time point). In none of these organs did we observe fluores-
cence suggesting the presence of SP-DiI–labeled MSCs.
BLI Evaluation of MSCs after Intravenous Delivery
Yang et al. [46] have shown that MSCs localize to U87 xenografts
after intravenous delivery. Ntv-a MSCs transduced with Ad-Luc were
injected into the tail vein of mice 6 weeks after they were injected
with RCAS–PDGF-B and RCAS-IGFBP2. BLI signal was not ob-
served in any of the 12 mice at any of the imaging time points (1, 4,
7, and 10 days after MSC injection). Of the subgroups of animals killed
on days 1, 4, 7, and 10 after MSC injection, none demonstrated BLI
signal in the brain (Figure 3, E and F). Histologic analysis of the brains
(H&E) showed that 10 of the 12 mice demonstrated formation of in-
tracranial tumors (Figure 3G ). The visceral organs of three of the mice
Figure 2. Flow cytometric analysis for Ntv-a–derived MSCs. FACS
results forMSCs at passages 6 and 15 for themesenchymalmarkers
Sca-1 and CD9, the endothelial markers CD105 and CD31, the hema-
topoietic markers CD45 and CD11b, and the GSC marker CD133.
720 Tropism of MSCs for Endogenous Gliomas in Mice Doucette et al. Neoplasia Vol. 13, No. 8, 2011
were examined with BLI, and a positive signal was identified in the
lungs of each of these mice (data not shown).
MSCs Derived from Ntv-a Mice Do Not
Enhance Tumorigenicity
To determine whether MSCs derived from Ntv-a mice could en-
hance tumor formation in the PDGF-B–dependent glioma model,
we coinjected RCAS–PDGF-B and MSCs in newborn Ntv-a mice.
Escalating doses of MSCs were coinjected with RCAS–PDGF-B.
The median survival in the cohort of mice injected with RCAS–
PDGF-B alone was 77 days (range, 23-90 days). There was no statis-
tical difference in survival between the cohorts of mice coinjected with
RCAS–PDGF-B and Ntv-a–derived MSCs compared with the control
group injected with RCAS–PDGF-B alone. In the cohort coinjected
with 1 × 103 MSCs, the median survival was 90 days (range, 35-90 days;
log-rank test, P = .13). In the cohort coinjected with 1 × 104 MSCs, the
median survival was 64 days (range, 33-90 days; log-rank test, P = .16).
In the cohort injected with 1 × 105 MSCs, the median survival was
67 days (range, 41-90 days; log-rank test, P = .4).
Discussion
In this report, we exploit the advantages of the RCAS/Ntv-a mouse
model system to show for the first time that harvested MSCs are capa-
ble of localizing to endogenous high-grade gliomas after intra-arterial
Figure 3. Ad-Luc–transfected MSCs derived from Ntv-a mice track to endogenous brain tumors formed by coexpression of RCAS–PDGF-B
and RCAS-IGFBP2 in Ntv-a mice. (A) Whole mouse and brain of mouse at day 1 after intra-arterial MSC injection demonstrating BLI signal
over the right frontal region only. (B) Whole mouse and brain of mouse at day 1 after MSC injection. No BLI signal was observed in either the
whole mount or the harvested brain. A small, localized area of positive BLI signal was detected over the right ear, a nonspecific finding
probably indicating MSCs circulating in the external carotid artery. (C) Coronal section of the brain of the mouse in A, demonstrating tumor
in the right frontal lobe of the brain (indicated by arrow). (D) Coronal section (H&E) of the mouse brain in B, without any evidence of tumor
formation. (E) Whole mouse at day 1 after intravenous MSC injection, demonstrating absent BLI signal over the right frontal region. (F) Brain
ofmouse at day 1 after intravenousMSC injection. No BLI signal was observed in the brain. (G) Coronal section (H&E) of themouse brain in F,
demonstrating significant tumor formation (arrow).
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delivery. BLI confirmed that the MSCs in the tumors were viable, and
histologic studies showed that MSCs display tumor-specific tropism be-
cause we did not observe MSCs outside the tumor in the normal brain
in this model. The demonstration of the tumor-tropic capacity of
MSCs for endogenous gliomas that develop in their native micro-
environment provides crucial support for the clinical translation of
the strategy of using MSCs to deliver therapeutic agents to human pa-
tients with malignant gliomas.
Because previous studies have used engrafted tumors, the impact of
the stroma on systemically delivered MSCs, particularly from a differ-
ent species, has been unclear. Our results, however, definitively dem-
onstrate that bone marrow–derived MSCs can be autotransfused into
the donor and that these MSCs localize to tumors that arise endoge-
nously within the natural milieu of the brain; thus, the tropism of
MSCs for gliomas is not a result of an artificial interaction between
the MSCs, the tumor, and the microenvironment.
We used a model of high-grade glioma induced by overexpression of
PDGF-B and IGFBP2 to study tumor engraftment by MSCs. Tumors
arising from this combination of genes recapitulate the phenotypic fea-
tures of high-grade glioma, particularly microvascular proliferation. The
development of abnormal blood vessels may be critical for MSCs to
localize to gliomas, as previous work from our group has suggested that
areas of neovascularization in tumors may be necessary for MSCs to
gain entry into the tumor after intravascular delivery [22]. The use of
Figure 4. SP-DiI–labeled MSCs distribute throughout endogenously forming gliomas. (A) Whole mount of tumor-bearing mouse brain at
day 4 after injection of SP-DiI–labeled MSCs. (B) Photomicrograph (H&E; original magnification, ×200) of glioma induced by RCAS–
PDGF-B and RCAS-IGFBP2. (C) Fluorescence photomicrograph (original magnification, ×200) of tumor section, demonstrating SP-DiI–
labeled MSCs (red cells). (D) Merged fluorescence photomicrograph (original magnification, ×200) showing distribution of MSCs (red
cells) throughout the tumor mass (counterstained blue with DAPI). Scale bars, 100 μm.
Figure 5. Tumor engraftment by MSCs declines after day 4. (A) Median BLI signal detected in the brains of tumor-bearing Ntv-a mice at
days 1, 4, 7, and 10 after intra-arterial Ad-Luc MSC injection. (B) Median SP-DiI–labeled MSC colony count in the brains of tumor-bearing
Ntv-a mice at days 1, 4, 7, and 10 after intra-arterial SP-DiI–labeled MSC injection.
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PDGF-B to induce tumors is also of interest because we have recently
shown that PDGF-BB may be a critical mediator of MSC tropism to
gliomas [20,21]. Because the RCAS/Ntv-a glioma model is dependent
on PDGF-B to initiate tumor formation, it is possible that recruitment
of MSCs to the tumor was facilitated by PDGF-B expression in the
tumor. Further studies are needed to decipher the specific mechanism
underlying the tropism of MSCs for gliomas. Nevertheless, the poten-
tial for PDGF-B to mediate the tropism ofMSCs for gliomas is relevant
to the human disease because approximately a third of gliomas are de-
fined by the PDGF pathway activation [35]. Thus, the model described
herein to study the migration of MSCs to brain tumors is relevant to a
significant subset of human glioma patients.
Another strength of our study is that the time between RCAS vector
injection and the introduction of MSCs was at least 6 weeks. Because
these tumors were formed well in advance of MSC injection, it is un-
likely that the MSC migration observed in this study is a consequence
of the known ability of MSCs to track to areas of injury [47]. Because
all other studies to date have relied on intracranial injection of tumor
cell lines, it has always been uncertain whether the injury induced by
the injection was at least partly responsible for the localization of MSCs
to glioma. Because of the long latency in this study between injection of
the RCAS vector and injection of the MSCs, this is the first study to
demonstrate MSC migration to gliomas that is independent of tissue
injury in the brain. Thus, our study shows that the tropism of MSCs
for gliomas is a direct response to the tumor and not to brain injury.
Successful harvesting of functional MSCs from Ntv-a mice is also
significant because these mice are a mixture of different genetic back-
grounds and supports the translational application of this therapeutic
strategy to humans. In an extensive report describing the isolation of
MSCs from five independent strains of mice, Peister et al. [42] noted
that each strain demonstrated variable expansion in different types of
culture media. Ntv-a mice are derived from four strains: C57BL/6,
BALB/C, FVB/N, and CD1. We determined that the optimal growth
medium was α-MEM, which resulted in robust cell growth. Although
previous studies have shown that hMSCs migrate to xenograft tumors
in mice, we are the first, to our knowledge, to show that it is possible to
obtain MSCs from a mouse, expand them in culture, and deliver these
MSCs into the same mouse bearing an endogenously formed intra-
cranial glioma. This strategy exactly mimics the approach that will be
used in humans and, therefore, is clinically important.
The intra-arterial route of delivery was required for a successful sys-
temic delivery of MSCs to brain tumors in our model. We observed
BLI signal in the region of the tumor (i.e., the right frontal lobe) from
Ad-Luc MSCs in 100% of mice harboring tumors. As we have dem-
onstrated previously, BLI can be used to track murine MSCs in brain
tumors in vivo [16]. We were able to demonstrate BLI signal in tumor-
bearing mice through day 7 after injection but not at day 10. We sus-
pect that the cells lose their viability over time, and this observation is
supported by our work showing only rare visualization of MSCs be-
yond 14 days after injection of human MSCs into nude mice bearing
U87 xenografts [unpublished data]. Because the decline in the MSC
activity over time has been observed in both the immunocompetent
RCAS/Ntv-a and immunodeficient systems, the loss of viability appears
to be independent of the immune status of the host. This may be an
advantage to usingMSCs as delivery vehicles because they may deliver a
therapeutic agent and then gradually disappear.
Although a positive BLI signal verified delivery of MSCs to the re-
gion of the tumor (i.e., right frontal area), we relied on SP-DiI–labeled
MSCs to confirm engraftment of MSCs throughout the tumor mass.
Mice injected with SP-DiI–labeled MSCs after RCAS vector injection
had labeled MSCs distributed throughout the tumor, but these did not
appear in non–tumor-bearing areas. The number of MSCs engrafted
into the tumor declined after day 4, consistent with our observation
from the mice injected with Ad-Luc MSCs that these cells have de-
creased viability over time. This result confirms the tumor-specific tro-
pism of MSCs and their ability to insinuate themselves throughout the
tumor mass. In contrast, intravenous delivery of MSCs did not result in
successful engraftment of Ad-LucMSCs.We did detect Ad-LucMSCs in
the thoracic cavity of the animals, and we interpret this result to mean that
MSCs were trapped in the lung parenchyma. It is possible that if we had
imaged at later time points, MSCs would have been able to engraft the
tumor after passing into the arterial circulation.We suspect, however, that
this would be a much smaller population of cells compared with intra-
arterial delivery and that their viability would be questionable. Other
investigators have had success with intravenous delivery of MSCs. For ex-
ample, Yang et al. [46] recently demonstrated that hMSCs migrate to
brainstem glioma xenografts in nude mice after intravenous injection.
However, in other studies using human neural stem cells to track to in-
tracranial xenografts in nude mice, migration to tumors was observed after
intravenous delivery but at a much lower efficiency compared with di-
rect intratumoral injection [10]. Although our group has had success with
intra-arterial delivery of hMSCs, we have been unable to demonstrate
effective delivery of hMSCs through intravenous injection to intracranial
xenografts in nude mice [16].
The ability of MSCs to be engineered to deliver therapeutic agents
has been well described.MSCs have been engineered to secrete a variety
of therapeutic proteins, including interferon β, S-TRAIL, and others
[16,22,46,48–50]. These studies have demonstrated that delivery of
these agents through MSCs confers a survival benefit compared with
control animals. Virtually all of these studies have relied on xenograft
models in immunocompromised mice, however. Limitations to using
gene-based therapies through MSC delivery remain, however, par-
ticularly with respect to the successful expression of a potentially ther-
apeutic gene from a short-lived MSC. Although our study was not
designed to evaluate a therapeutic benefit fromMSC-delivered therapy,
the results suggest that such a strategy would be viable in endogenous
tumors in an immunocompetent host. Studies evaluating the thera-
peutic benefit of MSCs in the RCAS/Ntv-a glioma model are cur-
rently underway.
Conclusions
In this study, MSCs from Ntv-a mice were successfully derived from
a heterogeneous population of bone marrow cells. These cells were
carried from harvest, and characterization through injection and en-
graftment of tumors generated endogenously in an immunocompe-
tent host. These results lend credence to the concept of using MSCs
as delivery vehicles for glial neoplasms in humans.
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